Download presentation
Presentation is loading. Please wait.
1
Targeted Care for COPD
2
Introduction
3
GOLD Recommendations: Initial Pharmacologic Treatment
4
GOLD Recommendations: Management Cycle
5
GOLD Recommendations: Follow-up Pharmacological Treatment
6
Pros
7
Percent Annual Rate Reduction of Moderate/Severe Exacerbations of COPD
8
Blood Eosinophil Counts, Exacerbations, and Response to the Addition of Inhaled Fluticasone to Vilanterol in COPD
9
Blood Eosinophils: Response to Beclomethasone/Formoterol in COPD Exacerbation Rate (FORWARD study)
10
Modeling Blood EOS to Identify Response to Budesonide in COPD – Post-Hoc Analysis
11
IMPACT Study: Blood Eosinophil Counts and Treatment Response
12
Predictors of Exacerbation Risk and Response to Budesonide: Post-hoc Analysis of 3 Randomized Trials
13
Cons
14
IMPACT Study: Blood Eosinophil Counts and Treatment Response
15
Pneumonia Risk in COPD Patients Receiving ICS Alone or in Combination (TORCH Study)
16
Relative Effect of ICS-Containing Medications on ECOPD vs Pneumonia
17
Blood Eosinophil Count and Pneumonia Risk in COPD: A Patient-Level Meta-Analysis
18
The Risk of Mycobacterial Infections Associated With ICS Use
19
ICS and the Risks of Diabetes Onset and Progression
20
Withdrawal of Inhaled Glucorticoids and Exacerbations of COPD
21
Eosinophilia, Frequent Exacerbations, and Steroid Response in COPD
22
Long-term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in COPD: SUNSET Trial
23
ICS in COPD: Friend or Foe?
24
ICS in COPD
25
Abbreviations
26
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.